Genmab A (GMAB) Other Accumulated Expenses (2018 - 2025)

Genmab A (GMAB) has reported Other Accumulated Expenses for 6 consecutive years, with $31.0 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses rose 69.13% year-over-year to $31.0 million; the trailing twelve-month figure through Dec 2025 stood at $31.0 million (up 69.13% YoY), and the FY2025 full-year result was $31.0 million, up 69.13% from the prior year.
• Other Accumulated Expenses rose to $31.0 million in Q4 2025 per GMAB's latest filing, from $18.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $14.0 billion in Q4 2023 and bottomed at $18.3 million in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $4.7 billion across 3 years, with a median of $31.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses tumbled 99.87% in 2024, then surged 69.13% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $14.0 billion in 2023, then tumbled by 99.87% to $18.3 million in 2024, then soared by 69.13% to $31.0 million in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $31.0 million, $18.3 million, and $14.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.